---All---
  • ---All---
  • Accession
  • Catalog #

FGFR4 Antibody (N-term) Blocking PeptideSynthetic peptide

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
BP7639a 0.1 mg 400 ul In Stock $ 45.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

FGFR4 Antibody (N-term) Blocking Peptide - Product info

Primary AccessionP22455
Clone Names2062611
Calculated MW87954 Da

FGFR4 Antibody (N-term) Blocking Peptide - Additional info

Gene ID 2264
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP7639a was selected from the N-term region of human FGFR4 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format
The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

FGFR4 Antibody (N-term) Blocking Peptide - Protein Information

Name FGFR4
Synonyms JTK2, TKF
Function
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling
Cellular Location
Cell membrane; Single-pass type I membrane protein. Endosome. Endoplasmic reticulum. Note=Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane
Tissue Location
Expressed in gastrointestinal epithelial cells, pancreas, and gastric and pancreatic cancer cell lines

FGFR4 Antibody (N-term) Blocking Peptide - Related products

AM7936a: FGFR4 Antibody (Ascites)

AM7936b: FGFR4 Antibody

AP7639a: FGFR4 Antibody (N-term)

AP7639d: FGFR4 Antibody

RI11998: FGFR4 predesign siRNA

BP7639a: FGFR4 Antibody (N-term) Blocking Peptide

BP7639d: FGFR4 Antibody Blocking Peptide

AO1117a: FGFR4 Antibody

AO1262a: FGFR4 Antibody

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

FGFR4 is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. The genomic organization of the gene, compared to members 1-3, encompasses 18 exons rather than 19 or 20. Although alternative splicing has been observed, there is no evidence that the C-terminal half of the IgIII domain of this protein varies between three alternate forms, as indicated for members 1-3. This particular family member preferentially binds acidic fibroblast growth factor and, although its specific function is unknown, it is overexpressed in gynecological tumor samples, suggesting a role in breast and ovarian tumorigenesis.

REFERENCES

Jezequel, P., et al., Br. J. Cancer 90(1):189-193 (2004).Qian, Z.R., et al., J. Clin. Endocrinol. Metab. 89(4):1904-1911 (2004).Yu, S., et al., J. Biol. Chem. 278(22):19597-19602 (2003).Becker, N., et al., Cancer Epidemiol. Biomarkers Prev. 12(6):582-583 (2003).Takenaka, H., et al., Arch. Dermatol. Res. 294(7):331-338 (2002).